Olema Pharmaceuticals (OLMA) Invested Capital (2020 - 2026)
Olema Pharmaceuticals (OLMA) has 7 years of Invested Capital data on record, last reported at $480.5 million in Q1 2026.
- On a quarterly basis, Invested Capital rose 25.3% to $480.5 million in Q1 2026 year-over-year; TTM through Mar 2026 was $480.5 million, a 25.3% increase, with the full-year FY2025 number at $478.6 million, up 17.02% from a year prior.
- Invested Capital reached $480.5 million in Q1 2026 per OLMA's latest filing, roughly flat from $478.6 million in the prior quarter.
- Over the last five years, Invested Capital for OLMA hit a ceiling of $480.5 million in Q1 2026 and a floor of $161.6 million in Q2 2023.
- A 5-year average of $285.2 million and a median of $253.9 million in 2023 define the central range for Invested Capital.
- Peak YoY movement for Invested Capital: crashed 33.99% in 2023, then surged 62.26% in 2025.
- Tracing OLMA's Invested Capital over 5 years: stood at $197.5 million in 2022, then grew by 28.52% to $253.9 million in 2023, then skyrocketed by 61.08% to $409.0 million in 2024, then increased by 17.02% to $478.6 million in 2025, then grew by 0.4% to $480.5 million in 2026.
- Business Quant data shows Invested Capital for OLMA at $480.5 million in Q1 2026, $478.6 million in Q4 2025, and $307.5 million in Q3 2025.